These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 31774391)

  • 61. Antibody-dependent enhancement of dengue virus infection inhibits RLR-mediated Type-I IFN-independent signalling through upregulation of cellular autophagy.
    Huang X; Yue Y; Li D; Zhao Y; Qiu L; Chen J; Pan Y; Xi J; Wang X; Sun Q; Li Q
    Sci Rep; 2016 Feb; 6():22303. PubMed ID: 26923481
    [TBL] [Abstract][Full Text] [Related]  

  • 62. An IRF-3-, IRF-5-, and IRF-7-Independent Pathway of Dengue Viral Resistance Utilizes IRF-1 to Stimulate Type I and II Interferon Responses.
    Carlin AF; Plummer EM; Vizcarra EA; Sheets N; Joo Y; Tang W; Day J; Greenbaum J; Glass CK; Diamond MS; Shresta S
    Cell Rep; 2017 Nov; 21(6):1600-1612. PubMed ID: 29117564
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Antibody with an engineered Fc region as a therapeutic agent against dengue virus infection.
    Ramadhany R; Hirai I; Sasaki T; Ono K; Ramasoota P; Ikuta K; Kurosu T
    Antiviral Res; 2015 Dec; 124():61-8. PubMed ID: 26522769
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Generation of Monoclonal Antibodies against Dengue Virus Type 4 and Identification of Enhancing Epitopes on Envelope Protein.
    Tang CT; Liao MY; Chiu CY; Shen WF; Chiu CY; Cheng PC; Chang GJ; Wu HC
    PLoS One; 2015; 10(8):e0136328. PubMed ID: 26309127
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Dengue virus compartmentalization during antibody-enhanced infection.
    Ong EZ; Zhang SL; Tan HC; Gan ES; Chan KR; Ooi EE
    Sci Rep; 2017 Jan; 7():40923. PubMed ID: 28084461
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Callithrix penicillata: a feasible experimental model for dengue virus infection.
    Ferreira MS; de Castro PH; Silva GA; Casseb SM; Dias Júnior AG; Rodrigues SG; Azevedo Rdo S; Costa e Silva MF; Zauli DA; Araújo MS; Béla SR; Teixeira-Carvalho A; Martins-Filho OA; Vasconcelos PF
    Immunol Lett; 2014; 158(1-2):126-33. PubMed ID: 24361035
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Immune response to dengue virus and prospects for a vaccine.
    Murphy BR; Whitehead SS
    Annu Rev Immunol; 2011; 29():587-619. PubMed ID: 21219187
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Dengue virus infection-enhancing activity of undiluted sera obtained from patients with secondary dengue virus infection.
    Moi ML; Takasaki T; Saijo M; Kurane I
    Trans R Soc Trop Med Hyg; 2013 Jan; 107(1):51-8. PubMed ID: 23296697
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Human keratinocyte cultures (HaCaT) can be infected by DENV, triggering innate immune responses that include IFNλ and LL37.
    López-González M; Meza-Sánchez D; García-Cordero J; Bustos-Arriaga J; Vélez-Del Valle C; Marsch-Moreno M; Castro-Jiménez T; Flores-Romo L; Santos-Argumedo L; Gutiérrez-Castañeda B; Cedillo-Barrón L
    Immunobiology; 2018 Nov; 223(11):608-617. PubMed ID: 30007822
    [TBL] [Abstract][Full Text] [Related]  

  • 70. First experimental in vivo model of enhanced dengue disease severity through maternally acquired heterotypic dengue antibodies.
    Ng JK; Zhang SL; Tan HC; Yan B; Martinez JM; Tan WY; Lam JH; Tan GK; Ooi EE; Alonso S
    PLoS Pathog; 2014 Apr; 10(4):e1004031. PubMed ID: 24699622
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Immunological and Pathological Landscape of Dengue Serotypes 1-4 Infections in Immune-Competent Mice.
    Rathore APS; Mantri CK; Tan MW; Shirazi R; Nishida A; Aman SAB; Morrison J; St John AL
    Front Immunol; 2021; 12():681950. PubMed ID: 34168651
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Cardif-mediated signaling controls the initial innate response to dengue virus in vivo.
    Perry ST; Prestwood TR; Lada SM; Benedict CA; Shresta S
    J Virol; 2009 Aug; 83(16):8276-81. PubMed ID: 19494017
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Viperin is induced following dengue virus type-2 (DENV-2) infection and has anti-viral actions requiring the C-terminal end of viperin.
    Helbig KJ; Carr JM; Calvert JK; Wati S; Clarke JN; Eyre NS; Narayana SK; Fiches GN; McCartney EM; Beard MR
    PLoS Negl Trop Dis; 2013; 7(4):e2178. PubMed ID: 23638199
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Acute dengue virus 2 infection in Gabonese patients is associated with an early innate immune response, including strong interferon alpha production.
    Becquart P; Wauquier N; Nkoghe D; Ndjoyi-Mbiguino A; Padilla C; Souris M; Leroy EM
    BMC Infect Dis; 2010 Dec; 10():356. PubMed ID: 21167041
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A mouse model for studying dengue virus pathogenesis and immune response.
    Williams KL; Zompi S; Beatty PR; Harris E
    Ann N Y Acad Sci; 2009 Sep; 1171 Suppl 1():E12-23. PubMed ID: 19751398
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The Involvement of Neuroinflammation in Dengue Viral Disease: Importance of Innate and Adaptive Immunity.
    Niranjan R; Muthukumaravel S; Jambulingam P
    Neuroimmunomodulation; 2019; 26(3):111-118. PubMed ID: 31352457
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Vav proteins do not influence dengue virus replication but are associated with induction of phospho-ERK, IL-6, and viperin mRNA following DENV infection
    Cowell E; Jaber H; Kris LP; Fitzgerald MG; Sanders VM; Norbury AJ; Eyre NS; Carr JM
    Microbiol Spectr; 2024 Jan; 12(1):e0239123. PubMed ID: 38054722
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Leukocyte immunoglobulin-like receptor B1 is critical for antibody-dependent dengue.
    Chan KR; Ong EZ; Tan HC; Zhang SL; Zhang Q; Tang KF; Kaliaperumal N; Lim AP; Hibberd ML; Chan SH; Connolly JE; Krishnan MN; Lok SM; Hanson BJ; Lin CN; Ooi EE
    Proc Natl Acad Sci U S A; 2014 Feb; 111(7):2722-7. PubMed ID: 24550301
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Temporally integrated single cell RNA sequencing analysis of PBMC from experimental and natural primary human DENV-1 infections.
    Waickman AT; Friberg H; Gromowski GD; Rutvisuttinunt W; Li T; Siegfried H; Victor K; McCracken MK; Fernandez S; Srikiatkhachorn A; Ellison D; Jarman RG; Thomas SJ; Rothman AL; Endy T; Currier JR
    PLoS Pathog; 2021 Jan; 17(1):e1009240. PubMed ID: 33513191
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Immunomodulation in dengue: towards deciphering dengue severity markers.
    Dash MK; Samal S; Rout S; Behera CK; Sahu MC; Das B
    Cell Commun Signal; 2024 Sep; 22(1):451. PubMed ID: 39327552
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.